Evommune's EVO756 Fails Phase 2b CSU Trial, Halting Development for Indication
EVMN sits 34% above its 52-week low of $13.885 on elevated volume (3.4× avg).
Summary
Evommune's drug candidate EVO756 failed its Phase 2b trial for chronic spontaneous urticaria (CSU), missing the primary endpoint, leading the company to halt development for this indication. This news follows an 8-K filed today disclosing the trial results. This is a significant setback for the company, eliminating a potential market for one of its key drug candidates and impacting its pipeline value. While EVO756 was reported safe and well-tolerated, its efficacy in CSU was insufficient. The company will continue evaluating EVO756 in other indications, with ongoing Phase 2b work in atopic dermatitis and initiated screening for migraine prophylaxis.
At the time of this announcement, EVMN was trading at $18.65 on NYSE in the Life Sciences sector, with a market capitalization of approximately $906.9M. The 52-week trading range was $13.89 to $33.20. This news item was assessed with negative market sentiment and an importance score of 9 out of 10. Source: Wiseek News.